Kang Xinuo (688185.SH): The inhaled tuberculosis reinforced vaccine started Phase I clinical trial in Indonesia and completed the enrollment of the first subject.

Wisdom Finance APP news, Kangxi Nuo (688185.SH) announced that the company has initiated Phase I clinical trials of the inhaled tuberculosis vaccine (5 adenovirus vector) (referred to as "inhaled tuberculosis vaccine") developed by the company in Indonesia recently, and the first subject has been enrolled in the Phase I clinical trial.